Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?

ABSTRACT: Over the past several years, there has been an increasing research effort focused on inhibition of protein-protein interactions (PPIs) to develop novel therapeutic approaches for cancer, including hematologic malignancies. These efforts have led to development of small molecule inhibitors of PPIs, some of which already advanced to the stage of clinical trials while others are at different stages of preclinical optimization, emphasizing PPIs as an emerging and attractive class of drug targets. Here, we review several examples of recently developed inhibitors of PPIs highly relevant to hematologic cancers. We address the existing skepticism about feasibility of targeting PPIs and emphasize potential therapeutic benefit from blocking PPIs in hematologic malignancies. We then use these example

SUBMITTER: Cierpicki T 

PROVIDER: S-EPMC4457300 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature